Physician profile
Morris P Elevado
NPI 1417941105
$233,344.68
in general payments reported to CMS, 2019-2025
41 companies · $16K in 2025
The $16K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68K · 2020: $16K · 2021: $30K · 2022: $51K · 2023: $30K · 2024: $22K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Food and Beverage: $14K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,125 · Travel and Lodging: $3,586 · Consulting Fee: $1,250 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,750.00 |
| Food and Beverage | $14,090.70 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,125.00 |
| Travel and Lodging | $3,586.22 |
| Consulting Fee | $1,250.00 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $136,367.54 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45,218.13 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $13,008.04 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Ucb, INC. | $9,949.90 | 2019-2020 | |
| Allergan, INC. | $9,771.88 | 2019-2020 | |
| Pfizer INC. | $3,706.84 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $2,840.03 | 2019-2024 | Linzess |
| Ardelyx, INC. | $2,044.92 | 2022-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $1,703.45 | 2021-2023 | Rebyota |
| Janssen Biotech, INC. | $1,489.96 | 2019-2025 | Tremfya, Stelara, Simponi |
| Phathom Pharmaceuticals, INC. | $1,412.62 | 2023-2025 | Voquezna |
| Qol Medical, LLC | $838.33 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $626.03 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $540.28 | 2021-2023 | |
| Braintree Laboratories, INC. | $526.89 | 2019-2025 | Suflave, Sutab |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $364.48 | 2022-2025 | |
| Medtronic, INC. | $330.93 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $298.65 | 2020-2025 | Ocaliva |
| Alnylam Pharmaceuticals INC. | $265.08 | 2023-2025 | Givlaari |
| Madrigal Pharmaceuticals | $262.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $246.97 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $235.66 | 2019-2024 | Dificid, Zinplava |
| Daiichi Sankyo INC. | $172.20 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $159.57 | 2022-2024 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $131.26 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $107.68 | 2021-2025 | |
| Boston Scientific Corporation | $103.39 | 2019-2022 | |
| Exact Sciences Corporation | $97.06 | 2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $89.22 | 2021 | |
| Aimmune Therapeutics, INC. | $82.51 | 2024-2025 | Vowst |
| Redhill Biopharma INC. | $75.63 | 2020 | |
| Covidien Lp | $51.97 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $45.33 | 2025 | |
| Celltrion USA INC. | $39.57 | 2025 | Vegzelma |
| Alfasigma USA, INC. | $38.96 | 2020 | |
| Organon LLC | $31.40 | 2023-2024 | Hadlima, Renflexis |
| Shionogi INC | $26.17 | 2019 | |
| Shire North American Group INC | $16.72 | 2019 | |
| Lucid Diagnostics INC. | $16.02 | 2024 | |
| Erbe USA INC | $7.58 | 2021 | |
| Romark Laboratories, Lc | $3.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Elevado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.